Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
patent losses
Pharma
Bristol Myers counters Revlimid generics with 3 new launches
As Revlimid generics take their toll, BMS feels confident it can shepherd its roster of new drugs toward more than $25 billion in sales by 2029.
Fraiser Kansteiner
Oct 26, 2022 9:37am
AbbVie's new Rinvoq win could help soften Humira's fall in 2023
Oct 24, 2022 11:51am
In reorganization, Amarin slashes US workforce, replaces CFO
Jun 6, 2022 11:10am
Takeda, Sun, Aurobindo, Eisai and more—Fierce Pharma Asia
May 13, 2022 9:45am
Takeda braces for Vyvanse's blockbuster patent loss
May 11, 2022 10:25am
Bristol busy boosting supply of Breyanzi, Abecma
Feb 4, 2022 11:06am
